Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1 mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID‐19 pandemic

OA Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361921/

Author(s)

Farah, Nadine

Burt, Richard

Ibrahim, Amr R

Baker, Robert

Kottaridis, Panagiotis D

Type

Journal Article

Date Issued

2020-08-01

Date Acceptance

2020-07-01

Citation

British Journal of Haematology, 2020, 190 (4), pp.e208-e210

URI

http://hdl.handle.net/10044/1/114348

URL

http://dx.doi.org/10.1111/bjh.16985

DOI

https://www.dx.doi.org/10.1111/bjh.16985

ISSN

0007-1048

Publisher

Wiley

Start Page

e208

End Page

e210

Journal / Book Title

British Journal of Haematology

Volume

190

Issue

4

Copyright Statement

© 2020 British Society for Haematology and John Wiley & Sons Ltd

Identifier

http://dx.doi.org/10.1111/bjh.16985

Publication Status

Published

Date Publish Online

2020-07-26